Chemotherapy Foundation Symposium 2011
24 Nov 2011
Chemotherapy Foundation Symposium 2011
New trastuzumab combinations for HER2 positive breast cancer
Antiangiogenic therapies for non-small cell lung cancer
Novel class of drug for ovarian cancer
Understanding tumour metastasis
Toxicity and side effect prevention
Lifetime achievement award and future work
Modelling cancer genomes
Chromosome instability in cancer development
RAS and drugable targets
New epigenetic targets and the role of DNA methylation fingerprints in cancer treatment
Highlights from day two of the 5th International Workshop